A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
← catalyst calendarSponsored by Astellas Pharma Inc (industry) · 4503.T — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60actual
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Company's strategic decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-16 | actual | When the study began enrolling |
| Primary completion | 2026-06-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Drug: ASP4396
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLTs) for ASP4369
measured Up to 21 days
Number of Participants with Adverse Events (AEs)
measured Up to 12 months
Number of Participants with Serious Adverse Events (SAEs)
measured Up to 12 months
Number of Participants with laboratory value abnormalities and/or AEs
measured Up to 12 months
Number of Participants with electrocardiogram (ECG) abnormalities and/or AEs
measured Up to 12 months
Number of Participants with vital sign abnormalities and/or AEs
measured Up to 12 months
Number of Participants with physical exam abnormalities and/or AEs
measured Up to 12 months
Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status score
measured Up to 12 months
Permalink · 4503.T's whole pipeline · Catalyst calendar · Every registered study · What changed